SC 13G/A | 2024-03-26 | EcoR1 Capital, LLC | Adaptimmune Therapeutics PLC | 164,424,420 | 10.7% | EDGAR |
SC 13G/A | 2024-02-14 | Long Focus Capital Management, LLC | Adaptimmune Therapeutics PLC | 12,086,915 | 5.3% | EDGAR |
SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Adaptimmune Therapeutics PLC | 65,815,692 | 4.8% | EDGAR |
SC 13G | 2024-01-30 | EcoR1 Capital, LLC | Adaptimmune Therapeutics PLC | 113,424,420 | 7.7% | EDGAR |
SC 13G/A | 2024-01-29 | BAILLIE GIFFORD & CO | Adaptimmune Therapeutics PLC | 95,472,840 | 7.0% | EDGAR |
SC 13G | 2023-11-08 | Long Focus Capital Management, LLC | Adaptimmune Therapeutics PLC | 6,582,798 | 2.9% | EDGAR |
SC 13G/A | 2023-07-10 | Matrix Capital Management Company, LP | Adaptimmune Therapeutics PLC | 233,845,110 | 17.3% | EDGAR |
SC 13D/A | 2023-03-30 | New Enterprise Associates 14, L.P. | Adaptimmune Therapeutics PLC | 102,478,672 | 10.3% | EDGAR |
SC 13G/A | 2023-02-14 | PFM Health Sciences, LP | Adaptimmune Therapeutics PLC | - | 3.0% | EDGAR |
SC 13G/A | 2023-02-13 | Capital World Investors | Adaptimmune Therapeutics PLC | 0 | 0.0% | EDGAR |
SC 13G/A | 2023-01-18 | BAILLIE GIFFORD & CO | Adaptimmune Therapeutics PLC | 103,019,634 | 10.5% | EDGAR |
SC 13G/A | 2022-12-02 | BAILLIE GIFFORD & CO | Adaptimmune Therapeutics PLC | 102,618,552 | 10.4% | EDGAR |
SC 13G | 2022-05-09 | PFM Health Sciences, LP | Adaptimmune Therapeutics PLC | - | 5.8% | EDGAR |
SC 13G/A | 2022-01-18 | BAILLIE GIFFORD & CO | Adaptimmune Therapeutics PLC | 82,538,112 | 8.8% | EDGAR |
SC 13G/A | 2021-02-16 | Matrix Capital Management Company, LP | Adaptimmune Therapeutics PLC | 233,845,110 | 25.2% | EDGAR |
SC 13G | 2021-02-16 | BAKER BROS. ADVISORS LP | Adaptimmune Therapeutics PLC | 58,985,262 | 6.4% | EDGAR |
SC 13G | 2021-02-16 | Capital World Investors | Adaptimmune Therapeutics PLC | 48,016,200 | 5.2% | EDGAR |
SC 13G | 2021-01-28 | BAILLIE GIFFORD & CO | Adaptimmune Therapeutics PLC | 62,146,680 | 6.7% | EDGAR |
SC 13G/A | 2020-02-14 | Matrix Capital Management Company, LP | Adaptimmune Therapeutics PLC | 168,000,000 | 26.6% | EDGAR |
SC 13G/A | 2020-02-14 | Capital World Investors | Adaptimmune Therapeutics PLC | 40,756,200 | 6.4% | EDGAR |